Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Michael Camilleri, MD
- Target Recruit Count
- 136
- Registration Number
- NCT03523273
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Yale University
- Target Recruit Count
- 13
- Registration Number
- NCT03500484
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 474
- Registration Number
- NCT03486392
- Locations
- 🇧🇪
CSL Arlon, Arlon, Belgium
🇧🇪AZ Delta, Roeselare, Belgium
🇨🇦Clinique des Maladies Lipidiques de Québec, Québec, Quebec, Canada
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 105
- Registration Number
- NCT03479762
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Soeborg, Denmark
Effects of Liraglutide in Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Claus Bogh Juhl
- Target Recruit Count
- 40
- Registration Number
- NCT03466021
- Locations
- 🇩🇰
Hospital of South West Jutland, Esbjerg, Denmark
🇩🇰Lillebaelt Hospital, Vejle, Denmark
Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 102
- Registration Number
- NCT03449654
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Individualized Obesity Pharmacotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 193
- Registration Number
- NCT03374956
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT03292185
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2020-08-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 834
- Registration Number
- NCT03235050
- Locations
- 🇸🇰
Research Site, Zilina, Slovakia
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 577
- Registration Number
- NCT03191396
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.